Core Points - GE HealthCare (GEHC) reported first-quarter 2025 adjusted earnings per share (EPS) of 1.01,exceedingtheZacksConsensusEstimateof91centsby111.23, reflecting a significant increase of 51.9% from the previous year [1] - GEHC's shares rose by 4.6% in pre-market trading following the earnings report, although the stock has declined 13% year-to-date compared to a 3.2% increase in the industry [1] Revenue Details - GEHC reported revenues of 4.78billion,markinga32.14 billion, up 4% year over year on a reported basis and 5% organically, with segment EBIT of 199million,a201.24 billion, up 1% year over year on a reported basis and 3% organically, with segment EBIT of 261million,a2753 million, up 1% year over year on a reported basis and 2% organically, while segment EBIT decreased by 41% year over year to 48million[5]−PharmaceuticalDiagnosticsrevenuestotaled632 million, reflecting a 6% year-over-year increase and an 8% organic increase, with segment EBIT of 205million,up15250 million, down from 419millionayearago[6]FinancialPosition−GEHCendedthefirstquarterwithcash,cashequivalents,andinvestmentstotaling2.47 billion, a decrease from 2.89billioninthepreviousquarter[7]−Totalassetsincreasedto33.59 billion from 33.09billionsequentially[7]2025Guidance−GEHealthCareupdateditsearningsandorganicrevenueguidancefor2025,nowexpectingadjustedEPSintherangeof3.90-4.10,downfromapreviousrangeof4.61-4.75,indicatingayear−over−yeardeclineof9−134.70 and $19.95 billion, respectively [9]